Treatment of Peripheral T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of GDPT regiment (gemcitabine，cisplatin,Prednisone ,Thalidomide

) for patients with Peripheral T-cell lymphoma.
Peripheral T-cell Lymphoma
DRUG: GDPT regimen|DRUG: CHOP regimen
Progression-free Survival, up to end of follow-up-phase (approximately 24 months)
Response Rate, 21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles, every 6 weeks,up to completion of treatment(approximately 18 weeks )|Overall Survival, up to the date of death (approximately 5 years)|Median Survival Time, 24 months
Patients with Peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy of CHOP. The investigators have been proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy regiment GDPT regiment (gemcitabine，cisplatin,Prednisone ,Thalidomide

) in the patients with Peripheral T-cell lymphoma.